SCHEMBL69094

SCHEMBL69094

O=[N+]([O-])c1c(Cl)cccc1CCl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.53
ALDH1A1 P00352 4/20 0.53
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
GRIN3A Q8TCU5 1/20 0.40
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
HSP90AA1 P07900 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14228218 0.85 ALDH1A1 (0.45) TSHRALDH1A1MAPTMAPK1L3MBTL1
SCHEMBL68857 0.83 ALDH1A1 (0.43) TSHRALDH1A1MAPTMAPK1L3MBTL1
SCHEMBL20476793 0.83 IDO1 (0.41) TSHRALDH1A1MAPTMAPK1L3MBTL1
SCHEMBL68734 0.83 MAPT (0.41) TSHRALDH1A1MAPTMAPK1L3MBTL1
SCHEMBL4146537 0.83 PNMT (0.53) TSHRALDH1A1MAPTMAPK1L3MBTL1
SCHEMBL670917 0.81 TSHR (0.58) TSHRALDH1A1MAPK1TDP1GRIN2D
SCHEMBL5604297 0.81 TSHR (0.69) TSHRALDH1A1MAPTMAPK1L3MBTL1
SCHEMBL22394589 0.80 HSP90AA1 (0.40) TSHRALDH1A1MAPTMAPK1L3MBTL1
SCHEMBL11158851 0.80 USP7 (0.41) TSHRALDH1A1MAPTMAPK1L3MBTL1
SCHEMBL20560654 0.79 ALDH1A1 (0.52) TSHRALDH1A1MAPTMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1865379-B1 Method for resist pattern formation, and process for device prodution CANON KK (JP) 2013-01-16 EP disclosed
CN-101086618-B Photosensitive compound, photosensitive composition, method for resist pattern formation, and process for elements production CANON KK 2012-06-20 CN disclosed
US-8129087-B2 Block copolymer and substrate processing method CANON KABUSHIKI KAISHA (JP) 2012-03-06 US disclosed
US-7651834-B2 Photosensitive compound, photosensitive composition, method for resist pattern formation, and process for device production CANON KABUSHIKI KAISHA (JP) 2010-01-26 US disclosed
US-20090311637-A1 BLOCK COPOLYMER AND SUBSTRATE PROCESSING METHOD CANON KABUSHIKI KAISHA (JP) 2009-12-17 US disclosed
US-20070287105-A1 PHOTOSENSITIVE COMPOUND, PHOTOSENSITIVE COMPOSITION, METHOD FOR RESIST PATTERN FORMATION, AND PROCESS FOR DEVICE PRODUCTION CANON KABUSHIKI KAISHA (JP) 2007-12-13 US disclosed
EP-1865379-A1 Photosensitive compound, photosensitive composition, method for resist pattern formation, and process for device prodution Canon Kabushiki Kaisha (JP) 2007-12-12 EP disclosed
CN-101086618-A Photosensitive compound, photosensitive composition, method for resist pattern formation, and process for elements production CANON KK (JP) 2007-12-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287105-A1 PHOTOSENSITIVE COMPOUND, PHOTOSENSITIVE COMPOSITION, METHOD FOR RESIST PATTERN FORMATION, AND PROCESS FOR DEVICE PRODUCTION RER1, C1R, CRY2 TSHR 1221/4885ALDH1A1 2569/4885MAPT 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.